Table 3.

Corresponding Genes Sensitive to Gefitinib in Both Mouse and Human Tumors

Mouse model
Human NSCLC
SymbolProbe setExpression levels
Fold change (TT/CT)SymbolGenbank IDExpressed class
CNCTTT
Areg1421134_at4682,4121,439−1.68AREGBC009799PD
Dusp31425608_at1,4321,444951−1.52DUSP3NM_004090PD
Nasp1440328_at1551313142.40NASPAF113699PR
Smad31450471_at16126345−5.84SMAD3NM_005902PD
Fmn11427671_a_at12211497.09FMN1AA059467PR
Tbc1d161442149_at24742571−5.98TBC1D16AA531128PD
Ap1g11460658_at27898−11.13AP1G1Y12226PD
Gpt21438385_s_at6211,461896−1.63GPT2AI356291PD
Cdkn2c1439164_at1117291.71CDKN2CAI357641PR
Pten1441593_at12419528−6.96PTENBC005821PD
Baiap21435128_at294274156−1.76BAIAP2AI339146PD
Foxm11448833_at70778653−14.83FOXM1BC006192PD
Tgfa1421942_s_at6720539−5.26TGFANM_003236PD
St131442775_at429302168−1.80ST13NM_003932PD
Eif4g21458431_at479728484−1.50EIF4G2X89713PD
  • NOTE: By using a genome-wide cDNA microarray to analyze 33 biopsy samples of advanced NSCLC from patients who had been treated with gefitinib, Kakiuchi et al. (16) identified 131 genes whose expression differed significantly between 7 responders and 10 nonresponders to the drug. We found that gefitinib treatment changed the expression levels for 15 of these 131 genes in mice tumors (fold change, >1.5), which correspond to the expression profiles predicting sensitivity to gefitinib in human NSCLC. Among these 15 genes, 8 of them were modulated by gefitinib toward to the normal level (fold change, >1.5). Symbol in bold font: genes modulated by gefitinib toward to the normal level.